Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus is a leading cause of kidney disease worldwide. A large and expanding array of treatments for diabetes is available to improve glycemic control, including newer classes of drugs, such as thiazolidinediones and incretin‐based therapies. The presence of impaired kidney function with reduced glomerular filtration rate should influence choices, dosing, and monitoring of hypoglycemic agents, as some agents require a dosing adjustment in patients with kidney disease and some are entirely contraindicated. This article reviews the clinical use of insulin and other antidiabetic therapies, focusing on pharmacokinetic properties and dosing in patients with advanced kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 2×
“03 cases per 1000 patient-years, much less than that seen with phenformin (14).”
BackgroundElbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Snyder, R. W., & Berns, J. S. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17346.x · Cited by 215 · cited 4×
“They also increase the peripheral utilization of insulin and decrease hepatic gluconeogenesis (26).”
BackgroundInfluentialSelf-citationBray, G. M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050459 · Cited by 52
PANCHAPAKESAN, U., POLLOCK, C., & SAAD, S. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01089.x · Cited by 25
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“In insulin-treated T2DM patients, insulin doses should be reduced by 25% when the eGFR is between 10-50 mL/min, and by 50% when the eGFR is 10 mL/min [332,333] .”
BackgroundScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
“toring of hypoglycaemic agents according to the reduction of GFR [10, 12, 13].”
BackgroundPharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients
Kukla, A., Hill, J., Merzkani, M., Bentall, A., Lorenz, E. C., Park, W. D., D’Costa, M., Kudva, Y. C., Stegall, M. D., & Shah, P. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000000971 · Cited by 73
Metadata
- Authors
- Reilly, J. B., & Berns, J. S.
- Venue
- Seminars in Dialysis
- Publisher
- Wiley
- Published
- 2010-03
- Volume
- 23
- Issue
- 2
- Pages
- 163-168
- ISSN
- 0894-0959 (ISSN-L)
- 1525-139X
- OpenAlex
- W2112475150
- Cited by
- 47
- References
- 7
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease. https://app.cochat.ai/papers/10.1111/j.1525-139x.2010.00703.x
- The paper
- Reilly, J. B., & Berns, J. S. (2010). Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease. Seminars in Dialysis. https://doi.org/10.1111/j.1525-139x.2010.00703.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.